+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liposomal Doxorubicin Market Size, Share & Trends Analysis Report by Product (Doxil/Caelyx, Lipodox, Myocet), Application (Multiple Myeloma, Ovarian Cancer, Breast Cancer, AIDS-related Kaposi's Sarcoma), Distribution Channel, and Region with Growth Forecasts, 2025-2033- Product Image
Liposomal Doxorubicin Market Size, Share & Trends Analysis Report by Product (Doxil/Caelyx, Lipodox, Myocet), Application (Multiple Myeloma, Ovarian Cancer, Breast Cancer, AIDS-related Kaposi's Sarcoma), Distribution Channel, and Region with Growth Forecasts, 2025-2033- Product Image
New

Liposomal Doxorubicin Market Size, Share & Trends Analysis Report by Product (Doxil/Caelyx, Lipodox, Myocet), Application (Multiple Myeloma, Ovarian Cancer, Breast Cancer, AIDS-related Kaposi's Sarcoma), Distribution Channel, and Region with Growth Forecasts, 2025-2033

  • PDF Icon

    Report

  • 125 Pages
  • September 2025
  • Region: Global
  • Grand View Research
  • ID: 5998933
REQUEST CUSTOMIZATION
Description Jump to:
The global liposomal doxorubicin market size was estimated at USD 1.38 Billion in 2025 and is projected to reach USD 2.38 billion by 2033, growing at a CAGR of 7.04% from 2025 to 2033. The rising number of cancer cases, particularly breast cancer, fuels the liposomal doxorubicin market.

Advancements in nanotech for innovative drug formulations further strengthen this market. Liposomal delivery revolutionizes cancer treatment by offering increased effectiveness and lower side effects than traditional forms. Furthermore, ongoing research to improve delivery and stability and explore new therapeutic applications propels the market's rapid growth.

Rising cancer diagnoses propel the liposomal doxorubicin market, as it offers targeted chemotherapy with reduced side effects, making it a preferred treatment. For instance, the International Agency for Research on Cancer (IARC) estimates 20 million new cancer cases in 2022, projected to rise to 35 million by 2050, highlighting a growing global cancer burden.

Nano-technological advancements in the drug delivery of liposomal doxorubicin are driving the market by increasing the demand for advanced liposomal doxorubicin formulations. For instance, according to a study published in ACS Publications, Nanobowl-supported liposomal DOX (DOX@NbLipo) is more resistant towards the plasma proteins and blood flow shear force that resulted in minimal drug leakage in the drug delivery at targeted tissue. The study showed that DOX@NbLipo led to prolonged survival of the mice (up to 50 days) compared to other controls. The DOX@NbLipo treatment also led to the biggest increase in the lifespan of the mice by 108.3%.

Ongoing research on liposomal doxorubicin for different indications is propelling the market. For instance, a study published in the European Journal of Cancer demonstrated the higher efficacy of TLD-1 (Novel liposomal doxorubicin) as compared to conventional doxorubicin formulations in patients with advanced solid tumors.

Global Liposomal Doxorubicin Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global liposomal doxorubicin market report based on product, application, distribution channel, and region:

Product Outlook (Revenue, USD Million, 2021-2033)

  • Doxil/Caelyx
  • Lipodox
  • Myocet
  • Others

Application Outlook (Revenue, USD Million, 2021-2033)

  • Breast Cancer
  • Ovarian Cancer
  • AIDS-related Kaposi’s Sarcoma
  • Multiple Myeloma
  • Other Solid Tumors

Distribution ChannelOutlook (Revenue, USD Million, 2021-2033)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segmental and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Application
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Liposomal Doxorubicin Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
Chapter 4. Liposomal Doxorubicin Market: Product Business Analysis
4.1. Product Market Share, 2024 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Doxil/Caelyx
4.4.1. Doxil/Caelyx Market, 2021-2033 (USD Million)
4.5. Lipodox
4.5.1. Lipodox Market, 2021-2033 (USD Million)
4.6. Myocet
4.6.1. Myocet Market, 2021-2033 (USD Million)
4.7. Others
4.7.1. Others Market, 2021-2033 (USD Million)
Chapter 5. Liposomal Doxorubicin Market: Application Business Analysis
5.1. Application Market Share, 2024 & 2033
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Breast Cancer
5.4.1. Breast Cancer Market, 2021-2033 (USD Million)
5.5. Ovarian Cancer
5.5.1. Ovarian Cancer Market, 2021-2033 (USD Million)
5.6. AIDS related Kaposi’s Sarcoma
5.6.1. AIDS related Kaposi’s Sarcoma Market, 2021-2033 (USD Million)
5.7. Multiple Myeloma
5.7.1. Multiple Myeloma Market, 2021-2033 (USD Million)
5.8. Other Solid Tumors
5.8.1. Other Solid Tumors Market, 2021-2033 (USD Million)
Chapter 6. Liposomal Doxorubicin Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2024 & 2033
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies Market, 2021-2033 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies Market, 2021-2033 (USD Million)
6.6. Online Pharmacies
6.6.1. Online Pharmacies Market, 2021-2033 (USD Million)
Chapter 7. Liposomal Doxorubicin Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
7.4. North America
7.4.1. North America Liposomal Doxorubicin Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
7.4.2. U.S.
7.4.2.1. U.S. Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.3. Canada
7.4.3.1. U.S. Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.4. Mexico
7.4.4.1. Mexico Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5. Europe
7.5.1. Europe Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.2. UK
7.5.2.1. UK Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.3. Germany
7.5.3.1. Germany Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.4. France
7.5.4.1. France Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.5. Italy
7.5.5.1. Italy Liposomal Doxorubici Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.6. Spain
7.5.6.1. Spain Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.7. Denmark
7.5.7.1. Denmark Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.8. Sweden
7.5.8.1. Sweden Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.9. Norway
7.5.9.1. Norway Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6. Asia-Pacific
7.6.1. Asia-Pacific Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.2. Japan
7.6.2.1. Japan Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.3. China
7.6.3.1. China Liposomal DoxorubicinMarket Estimates and Forecasts, 2021-2033 (USD Million)
7.6.4. India
7.6.4.1. India Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.5. Australia
7.6.5.1. Australia Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.6. South Korea
7.6.6.1. South Korea Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.7. Thailand
7.6.7.1. Thailand Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7. Latin America
7.7.1. Latin America Liposomal DoxorubicinMarket Estimates and Forecasts, 2021-2033 (USD Million)
7.7.2. Brazil
7.7.2.1. Japan Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.3. Argentina
7.7.3.1. China Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.2. South Africa
7.8.2.1. South Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Saudi Arabia Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.4. UAE
7.8.4.1. UAE Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.5. Kuwait
7.8.5.1. Kuwait Liposomal Doxorubicin Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Sun Pharmaceutical Industries Ltd.
8.5.1.1. Company Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Johnson & Johnson
8.5.2.1. Company Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Merck & Co., Inc.
8.5.3.1. Company Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Cipla
8.5.4.1. Company Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
8.5.5.1. Company Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Lupin
8.5.6.1. Company Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Cadila Pharmaceuticals
8.5.7.1. Company Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. SRS Life Sciences
8.5.8.1. Company Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. GSK plc
8.5.9.1. Company Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Pfizer Inc.
8.5.10.1. Company Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. Sanofi
8.5.11.1. Company Overview
8.5.11.2. Financial Performance
8.5.11.3. Product Benchmarking
8.5.11.4. Strategic Initiatives
8.5.12. Sigma-Aldrich Co.
8.5.12.1. Company Overview
8.5.12.2. Financial Performance
8.5.12.3. Product Benchmarking
8.5.12.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global liposomal doxorubicin market, by region, 2021-2033 (USD Million)
Table 4 Global liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 5 Global liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 6 Global liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 7 North America liposomal doxorubicin market, by country, 2021-2033 (USD Million)
Table 8 North America liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 9 North America liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 10 North America liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 11 U.S. liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 12 U.S. liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 13 U.S. liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 14 Canada liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 15 Canada liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 16 Canada liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 17 Mexico liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 18 Mexico liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 19 Mexico liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 20 Europe liposomal doxorubicin market, by country, 2021-2033 (USD Million)
Table 21 Europe liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 22 Europe liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 23 Europe liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 24 UK liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 25 UK liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 26 UK liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 27 Germany liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 28 Germany liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 29 Germany liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 30 France liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 31 France liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 32 France liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 33 Italy liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 34 Italy liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 35 Italy liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 36 Spain liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 37 Spain liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 38 Spain liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 39 Norway liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 40 Norwa liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 41 Norway liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 42 Denmark liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 43 Denmark liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 44 Denmark liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 45 Sweden liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 46 Swede liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 47 Sweden liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 48 Asia-Pacific liposomal doxorubicin market, by country, 2021-2033 (USD Million)
Table 49 Asia-Pacific liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 50 Asia-Pacific liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 51 Asia-Pacific liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 52 Japan liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 53 Japan liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 54 Japan liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 55 China liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 56 China liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 57 China liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 58 India liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 59 India liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 60 India liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 61 Australia liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 62 Australia liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 63 Australia liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 64 South Korea liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 65 South Korea liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 66 South Korea liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 67 Thailand liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 68 Thailand liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 69 Thailand liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 70 Latin America liposomal doxorubicin market, by country, 2021-2033 (USD Million)
Table 71 Latin America liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 72 Latin America liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 73 Latin America liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 74 Brazil liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 75 Brazil liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 76 Brazil liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 77 Argentina liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 78 Argentina liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 79 Argentina liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 80 Middle East & Africa liposomal doxorubicin market, by country, 2021-2033 (USD Million)
Table 81 Middle East & Africa liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 82 Middle East & Africa liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 83 Middle East & Africa liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 84 South Africa liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 85 South Africa liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 86 South Africa liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 87 Saudi Arabia liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 88 Saudi Arabia liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 89 Saudi Arabia liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 90 UAE liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 91 UAE liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 92 UAE liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
Table 93 Kuwait liposomal doxorubicin market, by product, 2021-2033 (USD Million)
Table 94 Kuwait liposomal doxorubicin market, by application, 2021-2033 (USD Million)
Table 95 Kuwait liposomal doxorubicin market, by distribution channel, 2021-2033 (USD Million)
List of Figures
Figure 1 Liposomal doxorubicin market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapeutic approach and disease outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Liposomal doxorubicin market dynamics
Figure 12 Liposomal doxorubicin market: Porter’s five forces analysis
Figure 13 Liposomal doxorubicin market: PESTLE analysis
Figure 14 Liposomal doxorubicin product market, 2021-2033 (USD Million)
Figure 15 Doxil/Caelyx market, 2021-2033 (USD Million)
Figure 16 Lipodox market, 2021-2033 (USD Million)
Figure 17 Myocet market, 2021-2033 (USD Million)
Figure 18 Others market, 2021-2033 (USD Million)
Figure 19 Liposomal doxorubicin application market, 2021-2033 (USD Million)
Figure 20 Breast cancer market, 2021-2033 (USD Million)
Figure 21 Ovarian cancer market, 2021-2033 (USD Million)
Figure 22 AIDS related Kaposi’s Sarcoma market, 2021-2033 (USD Million)
Figure 23 Multiple myeloma market, 2021-2033 (USD Million)
Figure 24 Other solid tumors market, 2021-2033 (USD Million)
Figure 25 Liposomal doxorubicin distribution channel market, 2021-2033 (USD Million)
Figure 26 Hospital pharmacies market, 2021-2033 (USD Million)
Figure 27 Retail pharmacies market, 2021-2033 (USD Million)
Figure 28 Online pharmacies market, 2021-2033 (USD Million)
Figure 29 Liposomal doxorubicin market revenue, by region
Figure 30 Liposomal doxorubicin regional marketplace: Key takeaways
Figure 31 North America liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 32 U.S. country dynamics
Figure 33 U.S. liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 34 Canada country dynamics
Figure 35 Canada liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 36 Mexico country dynamics
Figure 37 Mexico liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 38 Europe liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 39 UK country dynamics
Figure 40 UK liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 41 Germany country dynamics
Figure 42 Germany liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 43 France country dynamics
Figure 44 France liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 45 Italy country dynamics
Figure 46 Italy liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 47 Spain country dynamics
Figure 48 Spain liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 49 Norway country dynamics
Figure 50 Norway liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 51 Sweden country dynamics
Figure 52 Sweden liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 53 Denmark country dynamics
Figure 54 Denmark liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 55 Asia-Pacific liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 56 Japan country dynamics
Figure 57 Japan liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 58 China country dynamics
Figure 59 China liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 60 India country dynamics
Figure 61 India liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 62 Australia country dynamics
Figure 63 Australia liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 64 South Korea country dynamics
Figure 65 South Korea liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 66 Thailand country dynamics
Figure 67 Thailand liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 68 Latin America liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 69 Brazil country dynamics
Figure 70 Brazil liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 71 Argentina country dynamics
Figure 72 Argentina liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 73 MEA liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 74 South Africa country dynamics
Figure 75 South Africa liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 76 Saudi Arabia country dynamics
Figure 77 Saudi Arabia liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 78 UAE country dynamics
Figure 79 UAE liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 80 Kuwait country dynamics
Figure 81 Kuwait liposomal doxorubicin market, 2021-2033 (USD Million)
Figure 82 Company categorization
Figure 83 Company market position analysis
Figure 84 Strategic framework

Companies Mentioned

The leading players profiled in this Liposomal Doxorubicin market report include:
  • un Pharmaceutical Industries Ltd.
  • ohnson & Johnson Services, Inc.
  • erck & Co., Inc.
  • ipla
  • hanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • upin
  • adila Pharmaceuticals
  • RS Life Sciences
  • SK plc
  • fizer Inc.
  • anofi
  • igma-Aldrich Co.

Table Information

Report AttributeDetails
No. of Pages125
PublishedSeptember 2025
Forecast Period2025 - 2033
Estimated Market Value ( USD ) in 2025 $ 1.38 Billion
Forecasted Market Value ( USD ) by 2033 $ 2.38 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

Liposomal Doxorubicin Market Report by Product (Doxil/Caelyx, Lipodox, Myocet, and Others), Application (Leukemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Kaposi Sarcoma, and Others), and Region 2025-2033 - Product Image

Liposomal Doxorubicin Market Report by Product (Doxil/Caelyx, Lipodox, Myocet, and Others), Application (Leukemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Kaposi Sarcoma, and Others), and Region 2025-2033

  • Report
  • 145 Pages
  • Global
From
Liposomal Doxorubicin Market Report 2025 - Product Image

Liposomal Doxorubicin Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Liposomal Doxorubicin Market Report and Forecast 2025-2034 - Product Image

Liposomal Doxorubicin Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Doxorubicin - Global Strategic Business Report - Product Image

Doxorubicin - Global Strategic Business Report

  • Report
  • 288 Pages
  • Global
From
Doxorubicin Market - Global Forecast 2025-2032 - Product Image

Doxorubicin Market - Global Forecast 2025-2032

  • Report
  • 183 Pages
  • Global
From

About the Liposomal Doxorubicin Market

Liposomal Doxorubicin, a formulation of the chemotherapy drug doxorubicin, is part of a broader class of oncology drugs known as anthracyclines. This formulation encapsulates doxorubicin within liposomes, which are small, spherical vesicles composed of cholesterol and phospholipids. The liposomal encapsulation is designed to increase the drug's circulation time in the bloodstream, reduce the systemic toxicity traditionally associated with doxorubicin, and improve the targeting of the drug to cancerous tissues. This characteristic offers potential benefits in the treatment of various cancers, such as ovarian cancer, multiple myeloma, and Kaposi's sarcoma, especially in patients with HIV. Liposomal doxorubicin has been explored in numerous clinical trials and is employed in conjunction with other treatments to enhance therapeutic outcomes while trying to minimize adverse effects. Several companies are active in the liposomal doxorubicin market, contributing to its competitiveness and diversity. Notable players include Johnson & Johnson, through its subsidiary Janssen Products, which markets the drug under the name Doxil® in the United States. Other key companies involved in the production or distribution of liposomal doxorubicin include Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, and Pfizer, each offering generic or branded versions of the drug to meet the varying needs of oncology patients. These companies focus on research and development, production, and commercialization within the oncologic pharmaceutical sector. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.